Sonlicromanol - Khondrion
Alternative Names: KH 176Latest Information Update: 21 Nov 2024
Price :
$50 *
At a glance
- Originator Khondrion
- Class Antiparkinsonians; Benzopyrans; Piperidines; Small molecules
- Mechanism of Action Prostaglandin-E synthase inhibitors; Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Mitochondrial disorders
- No development reported Parkinson's disease
Most Recent Events
- 14 Nov 2024 US FDA approves IND application for sonlicromanol in Mitochondrial disorders
- 14 Nov 2024 Khondrion plans a pivotal phase III trial in Mitochondrial disorders (PO) in 2025
- 07 Nov 2024 Updated efficacy and adverse events data from the phase IIb trial in Mitochondrial disorders released by Khondrion